Question 1

What is combined oxidative phosphorylation deficiency 47?

Accepted Answer

Combined oxidative phosphorylation deficiency 47 (COXPD47) is a multisystem disorder that affects energy production and development. The condition is caused by pathogenic variants in the MRPS28 gene, which encodes a mitochondrial ribosomal protein essential for efficient oxidative phosphorylation. Affected individuals typically present with problems evident from birth, such as intrauterine growth retardation and failure to thrive, accompanied by a constellation of dysmorphic and metabolic features. Given the absence of precise prevalence data, this disorder is understood to be very uncommon, and ongoing research is needed to further delineate its frequency and natural history.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 47?

Accepted Answer

The clinical presentation of COXPD47 involves multiple organ systems and is characterized by a consistent pattern of features. Neurologically, affected individuals manifest generalized hypotonia and microcephaly, which can impact early development. Craniofacial dysmorphisms are prominent, including ptosis, posteriorly rotated ears, low-set ears, a long philtrum, and a round face, lending a recognizable appearance. Metabolic disturbances are evident with features such as failure to thrive, dehydration, hypoglycemia, metabolic acidosis, and increased circulating lactate levels, reflecting compromised mitochondrial energy production. Musculoskeletal signs include short palm, short neck, toe syndactyly, and cone-shaped epiphyses of the distal phalanges. Additional systemic features include sensorineural hearing impairment, dysphagia, cataract formation, hepatomegaly with elevated hepatic transaminase concentrations, and, in males, cryptorchidism. Not all individuals experience every feature, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 47?

Accepted Answer

Combined oxidative phosphorylation deficiency 47 results from pathogenic variants in the MRPS28 gene, which is crucial for the function of mitochondrial ribosomes. Disruption of MRPS28 leads to impaired protein synthesis within mitochondria, thereby affecting the cell’s energy production. The condition is inherited in an autosomal recessive manner, meaning that an affected individual has inherited two altered copies of the MRPS28 gene—one from each parent. As a result, parents typically do not show overt symptoms but carry one copy of the altered gene. This inheritance pattern implies that there is a 25% chance of recurrence with each pregnancy. Genetic counseling is recommended for families to better understand the implications and to explore reproductive options. Associated genes include MRPS28.

Question 4

How is combined oxidative phosphorylation deficiency 47 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 47 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 47 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation deficiency 47 relies on molecular genetic testing to identify pathogenic variants in the MRPS28 gene. The definitive diagnosis is achieved through gene sequencing and deletion/duplication analysis, which confirms the underlying genetic alteration. In addition, a thorough clinical evaluation is conducted by assessing the characteristic physical features such as intrauterine growth retardation, specific craniofacial dysmorphisms, and metabolic abnormalities including hypoglycemia and metabolic acidosis. Since many of these signs can be observed in other conditions, genetic testing is essential to distinguish COXPD47 from other disorders with overlapping features.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 47?

Accepted Answer

At present, there are no FDA-approved treatments specifically targeting combined oxidative phosphorylation deficiency 47. Consequently, management focuses on supportive care and addressing the symptoms as they present. Treatment is tailored to each individual and typically involves a multidisciplinary team that may include metabolic specialists, hepatologists, neurologists, and genetic counselors. Key aspects of care include nutritional support to combat failure to thrive, metabolic management to address hypoglycemia and acidosis, and physical therapy to aid in muscle strength and motor skills. Regular surveillance is an essential part of long-term management, with ongoing monitoring to detect complications early and to adjust care strategies as needed.

Question 7

What complications can arise from combined oxidative phosphorylation deficiency 47?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 47 may face various complications as they grow. These can include ongoing issues with muscle strength, developmental delays, and potential problems with multiple organ systems. Regular monitoring is important to catch any complications early and adjust care as needed.

Question 8

How does combined oxidative phosphorylation deficiency 47 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 47 can be challenging for both patients and their families. Daily life may involve managing symptoms like feeding difficulties, physical therapy for muscle strength, and regular medical appointments. Families often need to work closely with a team of specialists to ensure the best care and support.

Question 9

What is the prognosis for someone with combined oxidative phosphorylation deficiency 47?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation deficiency 47 varies widely. Some may experience significant challenges early in life, while others might have periods of stabilization. Ongoing care and support can improve quality of life, but predicting the exact course of the condition is difficult due to its variability.

Question 10

What specific symptoms should families look out for in combined oxidative phosphorylation deficiency 47?

Accepted Answer

Families should be aware of several specific symptoms associated with combined oxidative phosphorylation deficiency 47. These include growth delays, muscle weakness, distinctive facial features like low-set ears, and metabolic issues such as hypoglycemia. Not every individual will have all symptoms, and their severity can differ greatly.

Organ System	Phenotype Count	Example Features
Digestive system	3	Enlarged liver (hepatomegaly), Elevated circulating hepatic transaminase concentration, Difficulty swallowing (dysphagia)

Research Type	Count	% of Total
Laboratory research	18	55%

Kisho

combined oxidative phosphorylation deficiency 47

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 47

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 47?

What are the symptoms of combined oxidative phosphorylation deficiency 47?

What causes combined oxidative phosphorylation deficiency 47?

How is combined oxidative phosphorylation deficiency 47 inherited?

How is combined oxidative phosphorylation deficiency 47 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 47?

What complications can arise from combined oxidative phosphorylation deficiency 47?

How does combined oxidative phosphorylation deficiency 47 affect daily life for patients and families?

What is the prognosis for someone with combined oxidative phosphorylation deficiency 47?

What specific symptoms should families look out for in combined oxidative phosphorylation deficiency 47?

Explore clinical features

Recent Publications